Five insights shaping external innovation in healthcare today

Recent conversations across science, investment, and strategy continue to reveal where healthcare innovation is heading and what it will take to translate breakthrough ideas into meaningful patient impact. Through ongoing engagements with founders, investors, and industry leaders, several consistent themes have emerged that are actively informing how we think about external innovation, partnering, and drug discovery.

Much more than abstract observations, these insights are also shaping how our teams at Johnson & Johnson evaluate early-stage science, structure collaborations, and invest in the relationships that help define our future pipeline.

AI-driven discovery is accelerating, but scientific rigor remains essential

Artificial intelligence and machine learning are becoming increasingly influential tools in early drug discovery. When applied thoughtfully, they help researchers explore complex biological questions, identify new targets, and accelerate discovery. The most credible approaches combine computational innovation with strong biological grounding, integrating physics-informed modeling, multimodal datasets, and closed-loop experimentation that connects computational predictions with laboratory validation.

Even as these capabilities advance, the fundamentals of drug discovery remain unchanged. Validated biology, a clear target rationale, and disciplined experimental design continue to guide meaningful progress. Technology can strengthen discovery, but it does not replace scientific judgment. As AI tools mature, the field is developing a clearer understanding of where computational insight adds value and where human expertise remains essential.

The question in AI-enabled discovery isn't whether the technology works. The question is whether we're asking the right questions, and whether the science behind it is strong enough to make the answers meaningful.

Strong collaborations begin well before a transaction

Effective collaborations rarely begin with a deal discussion. Instead, they develop through sustained engagement, early alignment, and transparent conversations about risk. Organizations that engage potential collaborators early are often better positioned to navigate evaluation processes and build internal conviction. Clear differentiation, thoughtful milestone planning, and a well-defined value proposition help create productive dialogue between emerging companies and larger organizations.

Equally important is openness about both strengths and limitations, because honest conversations about uncertainty often build the trust needed for long-term collaboration.

The companies that succeed in search & evaluation aren't always the ones with the most impressive data packages. They're the ones who understand how to have a productive conversation about uncertainty - and who've built a relationship before they needed one.

Capital efficiency and structural clarity are increasingly important

The financing environment for healthcare innovation continues to change and grow. In response, many companies are placing greater emphasis on disciplined resource allocation and operational clarity. Clean deal structures, transparent ownership frameworks, and objective milestones are becoming foundational elements of successful financing strategies. Companies are also exploring dual-track approaches that maintain strategic flexibility while enabling continued progress on scientific and development milestones.

These approaches allow organizations to balance speed with long-term sustainability while keeping the focus on advancing promising science.

Corporate venture capital offers capabilities beyond funding

Corporate venture investors play a distinct role in the innovation ecosystem. In addition to capital, strategic investors often contribute scientific insight, development expertise, regulatory perspective, and operational experience. These capabilities can help emerging companies navigate complex stages of drug development and strengthen connections to broader development infrastructure.

For founders, understanding how to engage strategic investors differently from traditional venture capital firms can unlock additional value and support long-term growth.

Global innovation continues to evolve

Healthcare innovation is increasingly shaped by global collaboration. Capital flows, development expertise, and scientific talent are distributed across regions, creating new opportunities for collaboration and faster advancement of promising discoveries.

At the same time, organizations must move quickly while maintaining scientific discipline and regulatory rigor. Building durable relationships across the global ecosystem is becoming essential to sustaining progress.

Success in this environment depends on connecting strong science with thoughtful collaboration and a clear focus on patient impact.

Why these insights matter

Taken together, these insights reinforce that the most meaningful advances in healthcare rarely occur in isolation. Real progress depends on rigorous science, thoughtful capital deployment, and strong collaboration across the life sciences ecosystem. When these elements align, innovative ideas can move more effectively from discovery to development and ultimately to the patients who need them.

At Johnson & Johnson, we remain focused on connecting with the teams advancing promising research and supporting the relationships that help bring new therapies closer to patients.

If you are working on science with the potential to change how disease is treated or are interested in learning more about how Johnson & Johnson's external innovation group evaluates and supports early-stage innovation, you can start by visiting our website and connecting with our team today. We recommend subscribing to our newsletter to stay informed on upcoming events and the latest insights. Plus, follow JLABS on X for additional updates on news, events, and innovation highlights from across our global network.